Archives
-
Valemetostat (DS-3201): Dual EZH1/EZH2 Inhibition in Lymphom
2026-06-08
Valemetostat is a selective dual inhibitor of EZH1 and EZH2, achieving nanomolar potency against wild-type and mutant EZH2. It is indicated for relapsed or refractory follicular lymphoma, demonstrating high objective response rates and specificity, according to clinical and preclinical sources. This article clarifies its mechanism, benchmark data, and practical assay integration for epigenetic cancer therapy.
-
DiI (DiIC18(3)) Plasma Membrane Orange Fluorescent Probe Gui
2026-06-08
DiI (DiIC18(3)) addresses the need for selective, high-contrast plasma membrane labeling in live and fixed biological samples, particularly in applications like neuronal tracing and cell migration assays. It is not suitable for water-based protocols or for organelle-specific labeling beyond the plasma membrane.
-
Desert lncRNA HIDEN Regulates Human Endoderm Differentiation
2026-06-07
Lu et al. identify HIDEN, a desert lncRNA, as a critical regulator of human definitive endoderm differentiation. Their work reveals HIDEN's interaction with IMP1 stabilizes FZD5 mRNA, activating WNT signaling—a mechanism with broad implications for developmental biology.
-
HOTAIR Knockdown Modulates ARDS via miR-30a-5p/PDE7A Axis
2026-06-06
This study reveals that silencing the long non-coding RNA HOTAIR mitigates lipopolysaccharide-induced acute respiratory distress syndrome (ARDS) by regulating the miR-30a-5p/PDE7A axis. The findings illuminate a novel regulatory circuit underpinning ARDS pathogenesis and highlight potential targets for therapeutic intervention.
-
NF 449 for Platelet Aggregation Studies: Evidence & Best Use
2026-06-05
This article provides a scenario-driven, evidence-based guide to using NF 449 (SKU B6716) as a purinergic receptor antagonist in platelet aggregation and antithrombotic research. Bench scientists will find insights on assay optimization, data interpretation, and vendor reliability, enabling reproducible, high-sensitivity results with NF 449.
-
Mitomycin C: Antitumor Antibiotic Protocols for Cancer Resea
2026-06-05
Mitomycin C stands out as a benchmark antitumor antibiotic, empowering apoptosis signaling and combination therapy research with precise, reproducible protocols. This guide translates the latest mechanistic insights and workflow innovations into actionable steps, troubleshooting, and comparative advantages for advanced cancer model studies.
-
Staurosporine: Broad-Spectrum Kinase Inhibitor for Advanced
2026-06-04
Staurosporine, a potent broad-spectrum serine/threonine protein kinase inhibitor, unlocks precise control over apoptosis and angiogenic pathways in cancer research. This guide delivers actionable workflows, troubleshooting strategies, and translational insights for maximizing Staurosporine’s utility, with a spotlight on the latest mechanistic breakthroughs.
-
Berberrubine Modulates Metabolism and Gut Microbiota in NAFL
2026-06-04
This study demonstrates that berberrubine, a principal metabolite of berberine, effectively alleviates non-alcoholic fatty liver disease (NAFLD) through coordinated regulation of glucose and lipid metabolism and restoration of gut microbiota composition. The findings provide mechanistic clarity on berberrubine’s therapeutic action and highlight its potential as a functional material for NAFLD intervention.
-
Trichostatin A: Practical Epigenetic Regulation in Cancer Mo
2026-06-03
Trichostatin A (TSA) stands out as a gold-standard HDAC inhibitor for probing epigenetic regulation in cancer research. This guide delivers actionable protocols, troubleshooting strategies, and translational insights, empowering researchers to harness TSA’s full potential across cell-based and in vivo assays.
-
Sulfonamide Inhibition of hPON1: Sulfisomidine Mechanisms Ex
2026-06-03
This article examines the recent study assessing sulfonamide compound inhibition of human serum paraoxonase 1 (hPON1), with a focus on sulfisomidine's mixed-type inhibitory action. The findings clarify how sulfisomidine and related agents modulate hPON1 activity, with implications for research in enzyme kinetics, oxidative stress, and lipid metabolism.
-
EZ Cap™ Cy5 EGFP mRNA (5-moUTP): Dual-Reporter mRNA Delivery
2026-06-02
EZ Cap™ Cy5 EGFP mRNA (5-moUTP) from APExBIO revolutionizes gene delivery and translation efficiency assays with dual fluorescence and immune-evasive chemistry. Its Cap 1 structure, Cy5 label, and EGFP output make it the gold standard for real-time mRNA tracking and functional readouts in advanced cellular and nanoparticle studies.
-
Risedronate Sodium: FPPS Inhibitor Workflows for Bone & Lung
2026-06-02
Risedronate Sodium, a potent FPP synthase inhibitor, enables cutting-edge workflows in bone metabolism and emphysema research. Learn how nano-delivery, inhaled formulations, and robust in vitro protocols are revolutionizing experimental design and translational outcomes.
-
Exemestane (SKU A1296): Reliable Aromatase Inhibition in Bre
2026-06-01
This article addresses core workflow challenges in estrogen biosynthesis inhibition, focusing on the use of Exemestane (SKU A1296) for robust, reproducible breast cancer research. Leveraging evidence-backed answers to common laboratory scenarios, it demonstrates how APExBIO's Exemestane delivers dependable cytochrome P450 aromatase inhibition for cell viability, proliferation, and cytotoxicity assays.
-
Cisplatin in Cancer Research: Protocols, Workflows, and Trou
2026-06-01
Cisplatin (CDDP) remains indispensable for apoptosis modeling and tumor growth inhibition studies, but maximizing its translational impact requires workflow precision and resistance-aware strategies. This guide distills advanced protocol optimization, troubleshooting, and experimental innovation—including recent breakthroughs in stemness-targeted chemotherapy—using Cisplatin from APExBIO.
-
Ceftazidime: Third-Generation Cephalosporin in Infection Res
2026-05-31
Leverage Ceftazidime’s β-lactamase resistance and broad Gram-negative spectrum for advanced respiratory infection models and resistant pathogen workflows. This guide translates recent transmission dynamics research into actionable experimental protocols, troubleshooting, and comparative insights.